Tandem Diabetes Care, Inc.

Tandem Diabetes Care, Inc. faced notable stock volatility on March 27, 2026, with a significant decline. Over the past week and month, the stock has experienced substantial drops, while year-to-date performance shows a slight decrease. Long-term trends indicate a considerable decline over three and five years, alongside challenging financial metrics.

Tandem Diabetes Care, Inc. has experienced notable stock performance, gaining 9.13% on March 17, 2026. The company has outperformed the S&P 500 over the past week and month, while also showing resilience year-to-date. However, it faces challenges with low return on equity and a high debt-equity ratio.

Tandem Diabetes Care, Inc. reported a net profit of USD -18.95 million for the half-year, with quarterly net sales of USD 290.38 million and an operating profit margin of 4.4%. Despite reduced raw material costs and efficient inventory management, challenges persist, including a high debt-equity ratio and declining quarterly profits.

Tandem Diabetes Care, Inc. saw a significant rise in stock performance on February 24, 2026, reaching an intraday high of USD 29.65. The company has shown resilience with a 41.95% increase over the past week, despite longer-term challenges and a market capitalization of USD 1,679 million.

Tandem Diabetes Care, Inc. has seen significant stock activity, achieving an intraday high and notable one-day performance. Despite recent gains and strong institutional backing, the company faces long-term challenges, including a decline in one-year performance and low profitability, as indicated by its return on equity.

Tandem Diabetes Care, Inc. has experienced significant stock price fluctuations, currently at $28.26. The company shows mixed technical indicators, with bullish trends in MACD and Bollinger Bands, while the RSI indicates bearishness. Despite a challenging year, recent performance suggests a potential shift in momentum compared to the S&P 500.

Tandem Diabetes Care, Inc. has seen notable stock activity today, contrasting with the modest performance of the S&P 500. While the company has gained significantly over the past week, its year-long performance reveals a substantial decline. The firm continues to face challenges with profitability and has a market capitalization of USD 845 million.

Tandem Diabetes Care, Inc. faced notable volatility on November 6, 2025, with a significant stock decline. Over the past week and month, the stock has continued to drop, reflecting a troubling long-term performance. Financial metrics reveal challenges, including low return on equity and high debt levels, indicating ongoing difficulties.

Tandem Diabetes Care, Inc. has experienced significant stock fluctuations, with a 52-week high of $42.70 and a low of $9.98. Recent evaluations show mixed technical indicators, and the company's performance has lagged behind the S&P 500, reflecting ongoing challenges in the market.

Tandem Diabetes Care, Inc. saw a notable increase in its stock price on October 3, 2025, reflecting strong short-term performance compared to the S&P 500. However, the company faces long-term challenges, including significant declines over the past year and five years, alongside concerns regarding its financial health.

Tandem Diabetes Care, Inc. has seen a significant intraday gain, reaching USD 13.44, but the stock has struggled over the past year with a 72.7% decline. Financial metrics indicate low profitability, high debt reliance, and ongoing volatility, raising concerns about the company's market position and investor confidence.